research reports and media, page-355

I personally don't think any one thing is a silver bullet in respect of protecting IPPS. I think based on the analysis by 51 Capital and the PAR teams multi level approach (ie lock down the only TGA approved supplier, use Patents) will put us in good stead initially. IMO I think that over the longer term those thinking of putting PAR shares under the bed should be careful as with such a huge market challenges will come. It may be in the form of another supplier that is TGA approved or another drug / process that is more effective on OA etc etc ... Our advantage is like Coca Cola first mover into a market desperate for a solution and we (hopefully) will be first.... After that it will be gloves off.